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ABSTRACT
Introduction Botulinum neurotoxin- A (BoNT- A) is an 
accepted treatment modality for the management of 
hypertonia in children and young people with cerebral 
palsy (CYPwCP). Nevertheless, there are concerns about 
the long- term effects of BoNT- A, with a lack of consensus 
regarding the most meaningful outcome measures to 
guide its use. Most evidence to date is based on short- 
term outcomes, related to changes at impairment level 
(restrictions of body functions and structures), rather than 
changes in adaptive skills (enabling both activity and 
participation). The proposed study aims to evaluate clinical 
and patient reported outcomes in ambulant CYPwCP 
receiving lower limb BoNT- A injections over a 12- month 
period within all domains of the WHO’s International 
Classification of Functioning, Disability and Health and 
health- related quality of life (HRQoL).
Methods and analysis This pragmatic prospective 
longitudinal observational study will use a one- group 
repeated measures design. Sixty CYPwCP, classified as 
Gross Motor Function Classification System (GMFCS) 
levels I–III, aged between 4 and 18 years, will be recruited 
from an established movement disorder service in London, 
UK. Standardised clinical and patient reported outcome 
measures within all ICF domains; body structures and 
function, activity (including quality of movement), goal 
attainment, participation and HRQoL, will be collected 
preinjection and at 6 weeks, 6 months and up to 12 
months postinjection. A representative subgroup of 
children and carers will participate in a qualitative 
component of the study, exploring how their experience of 
BoNT- A treatment relates to clinical outcome measures.
Strengths and limitations of this study
 ► To our knowledge, this is the first published use of 
the ‘Quality Function Measure’ to objectively evalu-
ate quality of movement (QoM) following Botulinum 
neurotoxin- A (BoNT- A) treatment and explore 
whether any change in QoM translates into chang-
es in outcome within activities, participation and 
health- related quality of life.
 ► This pragmatic mixed methods observational study 
will evaluate response to lower limb BoNT- A in-
jections in ambulant children and young people 
with cerebral palsy using standardised outcome 
measures within all domains of the International 
Classification of Functioning, Disability and Health 
(ICF) over a 12- month period.
 ► This study is designed to optimise targeting of 
BoNT- A treatment by identifying patterns of re-
sponse to BoNT- A treatment across all ICF domains 
in order to assist clinicians and families in making 
informed decisions about future treatment.
 ► This is a pragmatic one- group study design, con-
ducted from a single tertiary (specialist children’s) 
centre. Participants will continue to receive their 
routine rehabilitation therapy and orthotic provision 
at local community level. Individualised intervention 
parameters may make study replication difficult in 
other settings.
 on A









pen: first published as 10.1136/bm





2 Katchburian LR, et al. BMJ Open 2021;11:e049542. doi:10.1136/bmjopen-2021-049542
Open access 
Ethics and dissemination Central London Research Ethics Committee 
has granted ethics approval (#IRAS 211617 #REC 17/LO/0579). Findings 
will be disseminated in peer- reviewed publications, conferences and 
via networks to participants and relevant stakeholders using a variety of 
accessible formats including social media.
INTRODUCTION
Cerebral palsy (CP) is the most common cause of physical 
disability in childhood.1 Although the initial brain insult is 
described as static, the effects of the neurological involve-
ment are dynamic and change with time and growth of 
the child.2 Increased tone (hypertonia) is considered one 
of the primary motor impairments in children and young 
people with cerebral palsy (CYPwCP)3 and a significant 
contributor to secondary musculoskeletal impairments 
impacting on activity and participation.4
Since the 1990s, intramuscular Botulinum neurotox-
in- A (BoNT- A) has become an internationally accepted 
treatment modality for the management of hypertonia 
in overactive muscle groups.5 BoNT- A once injected into 
the hypertonic muscle produces a ‘reversible’ tempo-
rary localised muscle weakness by blocking acetylcholine 
release at the neuromuscular junction. The pharma-
cological effect is said to last for 12–16 weeks, and the 
ability of BoNT- A to reduce focal hypertonia in ambulant 
CYPwCP has been well documented.6–8 While the effects 
can be observed within 24–72 hours following injection, 
the period of clinically useful relaxation is reported to last 
between 3 and 6 months.9 10
The progression of dynamic contracture to fixed 
contracture is a fundamental issue in the care of the child 
with CP. The period of decreased hypertonia following 
BoNT- A provides a ‘window of opportunity’ for therapy 
to address specific predetermined goals of rehabilita-
tion, such as stretching and strengthening of muscles, 
increased range of motion of joints, improved postural 
management and pain relief. Despite the temporary 
effect of injections, gains in motor function have been 
reported to last as long as 12 months.11
Several studies have demonstrated the benefits of 
BoNT- A injections for ambulant CYPwCP in Gross Motor 
Function Classification System (GMFCS) levels I–III,12 
particularly at single level use (injection at one level; eg, 
the calf complex to treat equinus foot posture).3 13–17 A 
meta- analysis of double- blind, randomised controlled 
trials (RCTs) confirmed superiority of BoNT- A over 
placebo injections into the calf complex on improve-
ment of gait in patients with spastic equinus.18 BoNT- A 
treatment, in combination with other rehabilitation 
treatments, has resulted in a significant improvement in 
functional goal attainment over and above those in a non- 
BoNT- A treatment group,19 with improvements in gait 
parameters, pain reduction and splint tolerance.20–23
Nevertheless, despite positive outcomes for single 
level use, RCTs of the effectiveness of multilevel use of 
BoNT- A injections report mixed results.24 25 Although a 
recent systematic review of interventions for CYPwCP, 
identified BoNT- A treatment as one of few interventions 
with a sound evidence base26, a recent Cochrane Collab-
oration report by Blumetti et al27 showed less favourable 
results. The report reviewed 31 studies, assessing 1508 
participants and concluded that there is limited evidence 
to show that BoNT- A, when compared to placebo or 
usual care, improves walking, joint motion, satisfac-
tion with outcome of treatment and muscle spasticity in 
CYPwCP. Sample sizes in BoNT- A studies are often small 
and predominately based on short- term outcome (3–6 
months) with few assessing outcomes beyond 6 months.
Although it is widely acknowledged that BoNT- A 
treatment is not a ‘stand- alone’ treatment, detailed 
information regarding the adjunctive measures used in 
conjunction with BoNT- A is often lacking, making eval-
uation of its efficacy difficult.28–30 Some authors have 
highlighted the difficulty in relating changes in impair-
ment measures following BoNT- A treatment to functional 
improvements in CYPwCP, with little reference made 
to minimal clinically important differences (MCIDs).24 
This raises concerns that current standardised outcome 
measures, focusing predominantly on impairment 
measures (without relating this to other domains of 
the ICF), may lack the sensitivity to pick up meaningful 
changes following injections, or indeed overestimate 
treatment effects if these do not relate to MCIDs, all 
highly pertinent when planning repeat treatment.24 27 31
Recent studies investigating pathophysiological changes 
within hypertonic muscle have highlighted potential 
histological changes following both single and repeated 
BoNT- A treatment.32 A number of authors have suggested 
potential harm following repeated BoNT- A use.33–36 
However, both positive and negative effects have been 
reported, and a variability in measurement techniques 
and muscles assessed makes comparison between studies 
challenging.37–42 Although BoNT- A has been described 
as a ‘reversible treatment’,43 some authors suggest that 
BoNT- A exposure in CYPwCP may be associated with 
impaired muscle growth in the short- term44–47 and poten-
tial long- term atrophy.41 45 48
The WHO’s International Classification of Functioning, 
Disability and Health (ICF) encourages evaluation of 
adaptive skills (enabling activities and participation) and 
health- related quality of life (HRQoL) in order to target 
interventions that are meaningful to CYPwCP and their 
families (figure 1). However, evidence for BoNT- A treat-
ment remains mostly related to measures of body func-
tions and structures, and less evidence pertains to activity 
and participation.22 25 49–51 Few trials have explored 
improvement in the activity and participation domains 
or HRQoL after BoNT- A injections,24 52 and qualitative 
data relating to CYP and caregivers experience are rarely 
incorporated.53–55
Longitudinal changes are not well characterised, and 
evidence of impact on CYPwCP is elusive. The uncertainty 
that exists around BoNT- A treatment has resulted in a 
call to extend the period that CYPwCP are followed up 
after BoNT- A treatment beyond the short- term, 12- week 
period,44 with an imperative to evaluate interventions 
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with BoNT- A using more sensitive outcome measures that 
evaluate meaningful aspects of health and quality of life 
for CYPwCP and families.35 44 56–58
Concern has been raised that BoNT- A treatment may 
be overprescribed for CYPwCP35 36 38 if there is little guid-
ance about which patients will benefit, risking poten-
tial harm if outcomes are unclear.38 59–61 While clinical 
evidence suggests that BoNT- A remains a valuable treat-
ment option,15 58 62 63 there is a need to optimise its use 
by developing clear guidelines and robust treatment 
algorithms in order to predict which children and young 
people will benefit from the addition of BoNT- A interven-
tion to their overall management programme and when 
it is preferable to consider other treatment options.
The Toxin Study
This paper describes the protocol for a pragmatic 
prospective longitudinal observational study in an estab-
lished paediatric movement disorder service in London, 
UK. As BoNT- A treatment is considered best practice care 
for focal hypertonia management in CP,19 21 48 there are 
practical and ethical concerns regarding the inclusion of 
a ‘no treatment’ control group and so a comparator was 
deemed not ethically appropriate.
The aims of this study are to:
1. Investigate clinical and patient reported outcomes (of 
body structures and function, quality of movement, ac-
tivities and participation and HRQoL) associated with 
lower limb BoNT- A injections in ambulatory CYPwCP 
over a 12- month period.
2. Determine any factors associated with a response to 
BoNT- A treatment.
3. Explore qualitatively how standardised clinical out-
come measures relate to the experiences of CYPwCP 
following BoNT- A treatment.
METHODS
Study design
This is a mixed methods study comprising of two phases:
Phase 1: to meet objectives 1 and 2, we will use a 
prospective longitudinal study using a one- group 
repeated measures design with each child acting as their 
own control.
Phase 2: to meet objective 3, we will conduct interviews 
with a subgroup of CYPwCP and parent/carers from 
phase 1 to elicit their experiences and views of change 
following BoNT- A treatment.
Using a convergent mixed methods approach, quanti-
tative data from phase 1 will be synthesised with qualita-
tive data from phase 2 in order to gain understanding of 
the impacts of BoNT- A treatment.55 64
Study sample and recruitment
Potential study participants will be identified from clinical 
lists of the Movement Disorder Service at Great Ormond 
Street Hospital for Children (GOSH). All eligible partic-
ipants will be invited to take part in phase 1 and will be 
enrolled sequentially. A subgroup of CYPwCP and their 
parents/primary carers will then be invited to participate 
in phase 2 following review at 6 months postinjection. 
Purposive sampling will be used to ensure a representa-
tive sample of CYPwCP within each GMFCS level.
Inclusion and exclusion criteria
Participants with a confirmed diagnosis of CP meeting the 
following criteria will be included: (1) ambulant, func-
tioning at GMFCS levels I–III; (2) aged between 4 and 18 
years; and (3) prescribed lower limb BoNT- A injections in 
their clinical management plan for dynamic hypertonia 
limiting functional goals or causing pain.
Children will be excluded if they have previously had: 
(1) orthopaedic surgery to the injected muscle; (2) neuro-
surgery for tone reduction (selective dorsal rhizotomy); 
(3) lower limb BoNT- A injections in the last 6 months, or 
currently have (4) unrelated musculoskeletal problems 
such as recent acute injury or congenital structural abnor-
mality; (5) no access to a block of therapy (defined as a 
minimum of 6 weekly sessions) postinjections; and (6) an 
inability to complete baseline assessments due to capacity, 
ability or willingness.
Parents: every effort will be made to support the inclu-
sion of all families invited to participate in the study 
(including those where English is not their first language). 
We will use translators when required to ensure that there 
is sufficient understanding to complete the measures.
INTERVENTION
Motor assessment
An experienced multidisciplinary team (consisting of a 
consultant paediatrician/neurologist and senior phys-
iotherapist) will identify muscle groups to be injected. 
Muscle selection will vary between participants according 
to the presence of dynamic hypertonia (based on clin-
ical assessment with reference to standard definitions65), 
related functional impairment and individual goals of 
the CYPwCP. All participants will receive a 6- week block 
Figure 1 WHO’s International Classification of Functioning, 
Disability and Health schematic representation of living with a 
health condition.
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of therapy post injection from their local therapy team, 
delivered locally in the community as per usual care. 
Details of dosage including frequency, location and type 
of therapy (eg, goal directed therapy and strengthening) 
together with participation activities will be recorded 
including any additional intervention such as casting or 
change in orthotic provision. This will be required in 
order to describe the content and parameters of usual 
care in as much detail as possible.66
Administration of BoNT-A
We will follow standard clinical practice prescription 
of BoNT- A at GOSH which involves administration of 
500U Dysport (abobotulinumtoxinA, Dysport Ipsen 
Ltd) diluted in 1ml of normal saline, up to a maximum 
dose of 30 units/kg/body weight or a total dose up to a 
maximum of 1000 units per injection session. All CYPwCP 
will continue to receive BoNT- A injections under ultra-
sound guidance as a day case, either under sedation with 
local analgesia or under general anaesthetic. Adverse 
events will be recorded, and standard reporting of dose 
per muscle and follow- up will be as per current clinical 
policy.
Training and fidelity
Clinical staff collecting study data are experienced 
members of the tertiary service with extensive expe-
rience of working with CYPwCP (mean 21 years, range 
13–33 years). A standardised protocol for measurement 
and documentation is used in the clinic, and an addi-
tional study manual with instructions for clinicians will be 
used to ensure consistency during the study. Two half- day 
training sessions will be provided for clinicians collecting 
study data prior to the start of recruitment. Monthly 
meetings with clinicians by the research team will ensure 
consistency and adherence to study protocol.
Staggered patient recruitment and data collection will 
commence in September 2017, and each participant 
will be followed up for a period of 12 months (figure 2). 
Data collection and final analysis of participant data are 
expected to be completed by September 2021. All deci-
sions regarding clinical care, assessment frequency and 
BoNT- A injections will continue as per usual clinical 
practice. Standardised clinical assessments and outcome 
measures will be performed at four time points T0–T3. 
The timings and rationale for these are summarised in 
table 1
All participants who have not undergone a surgical procedure 
will be assessed at T3, independent of outcome at T2. This 
will facilitate analysis of factors associated with changes in 
impairment, activity, participation and HRQoL following 
BoNT- A treatment and evaluate time to reinjection over 
12 months. The need for reinjection will be determined 
by clinical examination (documentation of a technical 
response, eg, change in MTS), evaluation of goal (Cana-
dian Occupational Performance Measure) scores and 
in consultation with families and local team as per usual 
clinical practice.
Validated outcome measures for all ICF domains
The standardised outcome measures used in the study 
are summarised within the ICF domains in figure 3 with 
administration details of the measures summarised in 
table 2. Outcome measures follow GOSH standard clin-
ical practice with primary outcome measures marked in 
italics.* Patient assessment takes between 60 and 90 min.
Classification of the participants
Gross Motor Function Classification System – Expanded and 
Revised (GMFCS-E&R)
The GMFCS- E&R12 is an internationally recognised five- 
level system to classify the motor abilities of CYPwCP aged 
4–18 years, with level I CYPwCP being identified as the 
most physically able and level V as the least. It is valid and 
reliable and frequently used in both research and clin-
ical practice. Only ambulant CYPwCP classified as GMFCS 
levels I–III will be included in this study.
Classification of CP
Participants are classified according to the distribution 
(unilateral or bilateral) and tone presentation (hyper-
tonia will be identified as predominantly spastic, dystonic 
or mixed in type) as identified by the guidelines of the 
surveillance of cerebral palsy in Europe network (SCPE).67
OUTCOME MEASURES
Primary outcome measures
Quality Function Measure (QFM) is an observational crite-
rion referenced measure designed to evaluate the quality 
of movement in standing and walking skills in CYPwCP.68 
It is used in conjunction with the Gross Motor Function 
Measure (GMFM) using dimensions D and E, which focus 
on ‘standing’ and ‘walking, jumping and running skills’, 
which are considered proxy clinical gait measures. The 
GMFM is the ‘gold standard’ tool for evaluating gross 
motor function in CYPwCP, evaluating ‘how much’ of a 
gross motor skill a child can perform.69 However, there 
are concerns regarding GMFM’s sensitivity in capturing 
subtle yet meaningful change postintervention, due to 
‘ceiling effects’ of the measure when used with ambulant 
CYPwCP in GMFCS levels I–III.22 68 70 The QFM scores 
movement quality and assesses ‘how well’ a child performs 
gross motor tasks.68 It has shown excellent rater and test–
retest reliability (Intraclass correlation (ICC) 0.89–0.97). 
Minimal detectable change estimates (6%–9%) suggest 
that the scale has potential as an evaluative measure (V 
Wright, personal communication, 8 May 2018). However, 
to date, there are no published studies evaluating the 
responsiveness of QFM following BoNT- A injections.
In order to minimise bias, the video analyst will be 
blinded to the stage of treatment and assessment time 
point (ie, pre T0 or post T 1–3 injection). To conceal 
these time points, each video containing GMFM D and 
E (standing and walking) dimensions is anonymised and 
randomly allocated a letter by a coworker not involved 
in the service. To minimise recall bias, a time lag will be 
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built in of 2 weeks and videos of at least 10 other children 
will be scored before scoring the video of the same child 
at a different assessment time point. This is in keeping 
with previous QFM reliability studies that suggest a gap 
of 2 weeks before evaluating test–retest scores.68 70 Data 
will be entered into a secure database without access 
to previous scores until scoring for all assessment time 
points is complete.
COPM is a goal attainment tool modified for use in 
the paediatric population and frequently used in neuro-
disability research.71–73 It identifies concerns regarding 
‘occupational performance issues’, that is, the ability to 
carry out functional tasks, allowing the identification 
of goals and has been used to document change post 
BoNT- A rehabilitation.74 In the paediatric population, 
areas of concern in a child’s self- care, activity and leisure 
are explored during the preassessment appointment with 
the clinical team. COPM has demonstrated high retest 
reliability (ICC 0.76–0.89), sensitivity to change and good 
content, construct and criterion validity for CYPwCP 
receiving BoNT- A.75 76 Families are asked to identify up to 
three areas of concern that they and their child hope to 
improve following lower limb BoNT- A injections. When-
ever possible, goals are set with the child’s input.77 The 
child and parents are asked to rate their perception of 
both current performance and their satisfaction with this 
performance on a 1–10 ordinal scale. A score change of 
two or more points is considered clinically significant.72 78
Figure 2 Study design flow chart of patient recruitment and data collection during the study. BoNT- A, Botulinum neurotoxin- A.  on A
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Secondary outcome measures
Modified Tardieu Scale (MTS) is a recognised clinical measure 
to differentiate dynamic spasticity from fixed contracture 
in a muscle. It determines the passive range of movement 
at two different movement velocities fast (R1) measuring 
dynamic muscle length and slow (R2) measuring static 
muscle length, with the relative difference between the 
two (R2–R1) determining the dynamic tone component 
of the muscle contracture.79 80 It is measured in degrees 
with a universal goniometer using standardised testing 
positions for each muscle. It has been postulated that the 
larger the dynamic tone component, the more amenable 
it is to treatment with BoNT- A.78 It is more effective than 
the Modified Ashworth Scale in identifying the presence 
of spasticity (88.9%, kappa=0.73, p=0.000) and the pres-
ence of contracture (77.8%, kappa=0.503, p=008).
Faces Pain Scale is a self- report measure of pain inten-
sity developed for children, which has been shown to 
have good psychometric properties for pain reporting 
(modified for use by carer when the child is unable to 
self- report). The scale shows a close linear relationship 
with visual analogue scales. It is measured by an ordinal 
scale from 0 to 10 with pictorial representation of faces. 
A change score of 2 or more is said to be clinically 
significant.81
Table 1 Timings of study assessments T0–T3
T0 Preinjection baseline measures 1–6 weeks before injection
T1 6 weeks postinjection Estimated time to reach target threshold for BoNT- A.
‘Evaluation of efficacy of injections’.
T2 6 months following injection Expected completion of pharmacological action.
‘Evaluation of retention of effects post injection’.
At T2, as per usual clinical practice, there are three 
possible outcomes for participants:
 ► Favourable response to injections with retention of 
effects – no further injections indicated at this time.
 ► Favourable response to injections – listed for a 
second injection cycle.
 ► Non favourable response to injections – discharged 
to other services (eg, neurosurgery/orthopaedics).
T3 12 months following initial injection End of study
Figure 3 Schematic representation of ICF domains including standardised outcome measures used in the study. ICF, 
International Classification of Functioning, Disability and Health.
 on A
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Selective Motor Control is a good discriminator of selective 
motor control and assesses a child’s ability to voluntarily 
and selectively control the dorsiflexors of the ankle.77 It 
is measured by an ordinal scale between 0 and 4. Higher 
score indicates better selectivity, inter- rater agreement has 
been shown to be moderate to good (kappa=0.58–0.77) 
with strong test–retest reliability (kappa=0.88–1).79 82
One Minute Fast Walk Test has been chosen as a proxy gait 
measure and is a good discriminator of functional ability 
for dynamic balance, muscle performance and endur-
ance.83 Participants walk for 1 min along a 9 m corridor 
at maximum speed without running. They are able to use 
their usual walking aids and orthoses. Distance is calcu-
lated to the nearest 10 cm. It shows concurrent validity 
with the GMFM, with significant correlation between 
GMFM score and distance walked (r=0.92) and good reli-
ability (ICC: 0.97).84
Modified Timed Up and Go is a good discriminator of 
balance, anticipatory postural control and functional 
mobility in CYPwCP. Participants are timed rising from 
a chair, walking 3 m to touch a star on the wall and 
returning to sit down as quickly as they can without 
running. Participants are able to use their usual walking 
aids and orthoses. The measure differentiates perfor-
mance between CYPwCP at GMFCS levels I–III. It has 
shown excellent inter- rater reliability (ICC 0.83–0.99)85
Participation Environment Measure – Child and Youth 
(PEM- CY) is an innovative parent- reported participa-
tion measure for use with CYP between 4 and 18 years. 
It measures CYPwCP’s participation at home (10 items), 
school (5 items) and community (10 items), taking 
into account the environmental challenges within each 
setting. Summary scores for participation frequency, 
child’s involvement and parental desire for change are 
calculated for all domains. PEM- CY has demonstrated 
good internal consistency (ICC 0.72–0.83) and test–retest 
reliability (ICC 0.76–0.89).86
Cerebral Palsy Quality of Life Measure (CPQOL) is an 
HRQoL assessment administered by questionnaire, 
specifically designed for CYPwCP. It quantifies ‘well- being’ 
across seven key HRQoL domains. Items are scored on 
a nine- point rating scale, then summed and averaged 
to generate seven domain scores. There are two child- 
reported (CPQOL- Child: 9–12 years and CPQOL- Teen: 
13–18 years) and two proxy- reported versions depen-
dent on child’s age and cognitive ability (CPQOL- Child 
Primary caregiver: 4–12 years and CPQOL- Teen Primary 
care giver: 13–18 years). The questionnaire designers 
have stipulated a minimum age of 9 years for child self- 
reporting, however significant disagreement has been 
reported between child and parent proxy reports in many 
HRQoL instruments, and the child’s perspective will be 
sought whenever possible in this study.87 The CPQOL has 
demonstrated good internal consistency (child ICC 0.74–
0.92; teen 0.81–0.96) and adequate test–retest reliability 
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Semistructured interviews
Interviews will be used to elicit CYPwCP and parent/
carers views of change following BoNT- A treatment. 
These are expected to last 60 min for parents and 
up to 30 min for children and will take place at home 
or in the hospital (depending on family preference). 
Interviews will be guided by a predetermined interview 
schedule, which will explore perceived change across all 
ICF domains to facilitate comparison with quantitative 
outcome measures, as well as investigate the acceptability 
of the standardised outcome measures used inphase 1 
of the study. Parents will be interviewed separately from 
CYPwCP, although individual preference for parents to 
be present or absent during interviews with their child 
will be respected. Interviews with CYPwCP will be tailored 
to their age, cognitive and communication ability using a 
variety of different techniques, including art- based activi-
ties. Offering a toolkit of different creative techniques will 
ensure that the activities will be accessible to all CYPwCP 
involved in the interviews, acknowledging their different 
skills and personalities and their cognitive and physical 
abilities that is particularly important in this population 
of CYP.90 To ensure a representative sample of partici-
pants for phase 2, CYPwCP with a good, moderate and 
poor response to toxin (determined by the clinical team 
at the 6- month assessment) within each GMFCS level (I–
III) will be invited to take part in phase 2. All interviews 
will be audio recorded with permission from participants.
Sample size
Phase 1: this study has been powered to detect a differ-
ence on one of the two primary outcome measures, the 
COPM. The sample size power calculation is based on 
anticipated change in the COPM goal performance 
at the primary end point T1 (6 weeks postinterven-
tion) after BoNT- A treatment. A change in score of 
2 or more points on the performance scale of the 
COPM would be considered clinically meaningful.72 78 
An earlier study of lower limb BoNT- A intramuscular 
injections yielded SD between 1.4 and 1.7 for COPM 
performance.77 Based on a conservative estimate using 
a mean change of two points on the COPM perfor-
mance scale (power 0.8, two tailed, p<0.05), 36 partici-
pants (12 in each GMFCS level) are required. Allowing 
for attrition and missing data over a 12- month period, 
a total of 60 participants (20 in each GMFCS level) will 
be recruited for phase 1 of the study.
As there are no studies reporting Quality Func-
tion Measure (QFM)68 as a primary outcome measure 
following BoNT- A injections, no data exist to inform a 
power calculation. It is anticipated that the results from 
this study will provide power calculation data for use in 
future multicentre trials using QFM.
Phase 2: a sample size of approximately 15 CYPwCP 
(five from each of the GMFCS levels I–III) and their 
parent/carer is anticipated to be sufficient to reach 
thematic saturation for the qualitative element of the 
study.91
Data analysis
Descriptive analysis of the prospective study will provide 
information on baseline characteristics of impairment, 
activity, participation and HRQoL. Means and SD will be 
used for normally distributed data and medians and IQRs 
for skewed data. Other demographic data will be described 
in a similar way with frequencies and proportions used 
for categorical information. The primary outcomes of the 
intervention will be assessed using generalised estimating 
equations for longitudinal analysis to evaluate differ-
ences in continuous data at postintervention time points. 
Multilevel regression models will be used to investigate 
the importance of the various potential predictors over 
a 12- month period on the four main outcomes: impair-
ment, activity, participation and HRQoL. First, univariate 
relationships will be explored. and then if appropriate, 
we will fit a multivariable model for each outcome.
All interviews will be transcribed verbatim, and tran-
scripts will be checked by the interviewer. Qualitative data 
will be analysed using Braun and Clarke’s six phase frame-
work for thematic analysis figure 4.92 Two researchers 
(LRK and KO) will undertake analysis of the transcripts 
to determine consistent themes and will then map these 
onto results from standardised outcomes. This will allow 
themes to emerge that can then be used to evaluate how 
closely standardised outcome measures relate to family 
experience.
Participant and data management
Electronic data will be managed through a secure database 
held in GOSH. Participants will be allocated an identifica-
tion code that will be used to deidentify their files and forms. 
Pseudonyms will be used in all reports and publications, and 
direct quotations will be anonymised. Paper documents and 
other manual files will be appropriately filed and stored 
securely in a locked filing cabinet at GOSH. Demographic 
information and consent forms will be stored separately to 
research data. Classification measures, child demographics 
and related information will be taken prior to baseline for 
the purposes of stratification and description of the sample. 
Audio and visual recordings will be uploaded onto secure 
password- protected encrypted National Health Service 
computers and deleted from the recording device imme-
diately after uploading. This protocol has been reviewed 
and approved by the Research and Development team and 
Caldecott Guardian at GOSH.
Patient and public involvement
Children and young people with CP and their parents 
have been involved in the development of this project, 
exploring the importance of the research, the appropri-
ateness of the research questions, the acceptability of the 
research methods and best methods for disseminating 
findings. Fifteen ambulant CYPwCP receiving BoNT- A 
treatment at GOSH and their parents were consulted 
individually. A wider population of CYPwCP and their 
parents were also consulted via the SCOPE website and 
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the advisory groups for CYPwCP at Brunel University and 
Young People’s Advisory Group at GOSH.
Reference group/steering group
Three parents (all mothers) and three CYPwCP (two boys 
and one girl (not participants)) continue advising on the 
study through membership of the study steering group 
(parents) or reference group (CYP). Three professionals 
(two physiotherapists and one doctor) are also part of 
the steering group. By including CYPwCP and families 
perspectives together with regular contributions from 
practising clinicians within the service, we hope to ensure 
the inclusion of important values and preferences from 
families and clinicians alike, ensuring that the findings of 
the study remain relevant and applicable to the manage-
ment of ambulant CYPwCP.24 93 94
DISCUSSION
This paper presents the protocol for a novel pragmatic 
prospective longitudinal observational study of BoNT- A 
use in ambulant CYPwCP at an established tertiary chil-
dren’s centre in the UK. It will measure outcomes across 
all domains of the ICF and HRQoL over a 12- month 
period to observe change and examine factors associated 
with positive or negative response to lower limb BoNT- A 
injections. The introduction of a standardised outcome 
measure, QFM, to evaluate any change in movement 
quality following BoNT- A treatment will further inform 
exploration of the relationship between tone reduction 
and changes in activity, as well as any influence on partic-
ipation and HRQoL for our cohort of CYPwCP. Mixed 
methods research designs are considered by many to be 
essential in the study of therapeutic interventions in CP.55 
Including qualitative study data will ensure that the expe-
riences of CYPwCP following BoNT- A injections are eluci-
dated, considered and further understood.
This study, by identifying patterns of response to 
BoNT- A injections in key aspects of health across all the 
ICF domains, will provide clinicians and families with 
meaningful information to inform future treatment 
planning and optimise the use of BoNT- A in CYPwCP. 
Evidence will be generated about the appropriateness 
of the outcome measures used in detecting meaningful 
change after BoNT- A injections as well as their accept-
ability to CYP. In addition, the relationship between the 
standardised outcome measures used to capture treat-
ment effect and the perception of outcome by children 
and their families will be investigated.
The results of this study will assist in the development of 
a pragmatic set of standardised clinical outcome measures 
(recognising minimum clinically important differences) 
in order to evaluate the effects of BoNT- A treatment in this 
cohort of patients. We hope this work will inform future 
evaluative research; working towards closer consensus on 
patient selection, injection frequency and consideration 
of how long treatment should continue, in order to assess 
the value of long- term use of BoNT- A treatment and its 
role in the management of CYPwCP.
A dissemination strategy has been devised to ensure the 
findings of this research are made widely accessible to fami-
lies and professionals in order to maximise impact on the 
care of CYPwCP. Working in partnership with parent groups 
will strengthen our dissemination strategy, ensuring find-
ings are shared in a variety of accessible formats reaching 
Figure 4 Braun and Clarke’s six- step approach to thematic 
analysis.
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a wide range of families, professionals, as well as academics 
and policy makers helping ensure the findings are trans-
lated into practice. We will disseminate the results of the 
study through international peer- reviewed journals and 
at national and international conferences. A social media 
strategy will also be developed to ensure dissemination of a 
plain language summary of findings.
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